MCID: GST012
MIFTS: 36

Gastroesophageal Junction Adenocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases, Cardiovascular diseases

Aliases & Classifications for Gastroesophageal Junction Adenocarcinoma

MalaCards integrated aliases for Gastroesophageal Junction Adenocarcinoma:

Name: Gastroesophageal Junction Adenocarcinoma 12 15
Adenocarcinoma of the Gastroesophageal Junction 73
Adenocarcinoma of Cardioesophageal Junction 12
Adenocarcinoma of Gastroesophageal Junction 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4944
NCIt 50 C9296
UMLS 73 C1332166

Summaries for Gastroesophageal Junction Adenocarcinoma

MalaCards based summary : Gastroesophageal Junction Adenocarcinoma, also known as adenocarcinoma of the gastroesophageal junction, is related to adenocarcinoma and esophagitis, and has symptoms including abdominal pain An important gene associated with Gastroesophageal Junction Adenocarcinoma is ERBB2 (Erb-B2 Receptor Tyrosine Kinase 2), and among its related pathways/superpathways are MAPK Pathway and Adherens junction. The drugs Herceptin and Capecitabine have been mentioned in the context of this disorder. Affiliated tissues include breast, testes and prostate, and related phenotype is cardiovascular system.

Related Diseases for Gastroesophageal Junction Adenocarcinoma

Diseases related to Gastroesophageal Junction Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 adenocarcinoma 10.8
2 esophagitis 10.3
3 helicobacter pylori infection 10.0
4 meningitis 9.8
5 lymphomatous meningitis 9.8
6 gastrointestinal system cancer 9.5 ERBB2 SNAI1
7 keratoconjunctivitis sicca 9.4 ERBB2 IL1B
8 pancreas adenocarcinoma 9.3 ERBB2 SNAI1
9 cercarial dermatitis 9.3 IL1B SNAI1

Graphical network of the top 20 diseases related to Gastroesophageal Junction Adenocarcinoma:



Diseases related to Gastroesophageal Junction Adenocarcinoma

Symptoms & Phenotypes for Gastroesophageal Junction Adenocarcinoma

UMLS symptoms related to Gastroesophageal Junction Adenocarcinoma:


abdominal pain

MGI Mouse Phenotypes related to Gastroesophageal Junction Adenocarcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 8.92 ERBB2 GUCY2C IL1B SNAI1

Drugs & Therapeutics for Gastroesophageal Junction Adenocarcinoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Herceptin 18 49 TRASTUZUMAB Genentech October 1998

Drugs for Gastroesophageal Junction Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 121)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
2
Cisplatin Approved Phase 3,Phase 2,Phase 1,Early Phase 1 15663-27-1 84093 441203 2767
3
Oxaliplatin Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 61825-94-3 5310940 9887054 43805 6857599
4
Trastuzumab Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 180288-69-1 9903
5
Docetaxel Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 114977-28-5 148124
6
Fluorouracil Approved Phase 3,Phase 2,Phase 1,Early Phase 1 51-21-8 3385
7
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
8
Levoleucovorin Approved, Investigational Phase 3,Phase 1,Phase 2 68538-85-2
9
Irinotecan Approved, Investigational Phase 3,Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
10
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
11
Cetuximab Approved Phase 3,Phase 2 205923-56-4 56842117 2333
12
Gefitinib Approved, Investigational Phase 3 184475-35-2 123631
13
Ramucirumab Approved, Investigational Phase 3,Phase 2,Phase 1 947687-13-0
14
Epirubicin Approved Phase 3,Phase 2,Early Phase 1 56420-45-2 41867
15
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
16
Pembrolizumab Approved Phase 3,Phase 2,Phase 1 1374853-91-4
17
Adenosine Approved, Investigational Phase 2, Phase 3 58-61-7 60961
18
leucovorin Approved, Nutraceutical Phase 3,Phase 1,Phase 2 58-05-9 143 6006
19
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 1,Phase 2 59-30-3 6037
20
Lapatinib Approved March 2007, Investigational Phase 2, Phase 3,Phase 3,Phase 1 231277-92-2, 388082-78-8 208908 9941095
21
s 1 (combination) Phase 3,Phase 2,Phase 1
22 Mitogens Phase 3,Phase 2,Phase 1
23 Angiogenesis Inhibitors Phase 2, Phase 3
24 Angiogenesis Modulating Agents Phase 2, Phase 3
25 Antibodies Phase 3,Phase 2,Phase 1
26 Immunoglobulins Phase 3,Phase 2,Phase 1
27 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
28 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Early Phase 1
29 Antimetabolites Phase 3,Phase 2,Phase 1,Early Phase 1
30 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Early Phase 1
31 Antimitotic Agents Phase 2, Phase 3,Phase 3,Phase 1
32 Analgesics Phase 3,Phase 1
33 topoisomerase I inhibitors Phase 3,Phase 2,Phase 1
34 Central Nervous System Stimulants Phase 3
35 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
36 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Early Phase 1
37 Opiate Alkaloids Phase 3
38 Endothelial Growth Factors Phase 3,Phase 1
39 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Early Phase 1
40 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Early Phase 1
41 Antiemetics Phase 3
42 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1
43 Appetite Stimulants Phase 3
44 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
45 taxane Phase 2, Phase 3
46 Alkylating Agents Phase 3
47 Ado-trastuzumab emtansine Phase 2, Phase 3,Phase 1
48 Mitomycins Phase 3
49 Nucleic Acid Synthesis Inhibitors Phase 3
50 Pharmaceutical Solutions Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 166)
# Name Status NCT ID Phase Drugs
1 Comparison Study of Brachytherapy and Endoscopic Stenting for Dysphagia in Esophago-Gastric Junction Cancer Unknown status NCT01786278 Phase 2, Phase 3
2 A Study of Apatinib Versus Docetaxol Patients With Advanced Gastric Cancer Unknown status NCT02409199 Phase 2, Phase 3 Docetaxel;apatinib
3 A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer Completed NCT02178956 Phase 3 BBI608;Paclitaxel
4 Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma Completed NCT00917384 Phase 3 Placebo
5 Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach Completed NCT01640782 Phase 3 Irinotecan, Leucovorin, 5-Fluorouracil, Docetaxel, Cisplatin;Leucovorin, 5-Fluorouracil
6 Gefitinib in Treating Patients With Esophageal Cancer That is Progressing After Chemotherapy Completed NCT01243398 Phase 3
7 Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer Completed NCT00678535 Phase 3 Cetuximab;Capecitabine;Cisplatin
8 A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma Completed NCT01170663 Phase 3 Placebo;Paclitaxel
9 Symptom Control With or Without Docetaxel in Treating Patients With Relapsed Esophageal Cancer or Stomach Cancer Completed NCT00978549 Phase 3 docetaxel;steroid therapy
10 Efficacy and Safety Study of the Combined Modality Therapy in Adenocarcinoma of the Esophago-gastric Junction Recruiting NCT01523015 Phase 2, Phase 3
11 Preoperative Concurrent Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Esophagogastric Junction Recruiting NCT01962246 Phase 2, Phase 3 Oxaliplatin; Capecitabine
12 A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer Recruiting NCT02898077 Phase 3 Ramucirumab;Paclitaxel;Placebo
13 S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment of Advanced or Recurrent Non-intestinal Type Gastric Adenocarcinoma Patients Recruiting NCT01824459 Phase 3 S-1;Oxaliplatin;Cisplatin
14 Preoperative Concurrent Chemoradiotherapy for Locally Advanced Gastroesophageal Junction or Upper Gastric Adenocarcinoma Recruiting NCT02193594 Phase 2, Phase 3 Adjuvant chemotherapy
15 Radical Gastrectomy With/Without HIPEC in Advanced Gastric Cancer Patients Recruiting NCT02381847 Phase 3
16 Adjuvant Capecitabine Versus Observation Alone in Curatively Resected Stage IB Gastric Cancer Recruiting NCT01917552 Phase 3 capecitabine
17 Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis Recruiting NCT02158988 Phase 3
18 Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus Recruiting NCT02509286 Phase 3 5-Fluorouracil;Leucovorin;Oxaliplatin;Docetaxel;Carboplatin;Paclitaxel
19 Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer Recruiting NCT00450203 Phase 2, Phase 3 capecitabine;cisplatin;Epirubicin;Lapatinib
20 A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061) Active, not recruiting NCT02370498 Phase 3 paclitaxel
21 Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE- Active, not recruiting NCT03019588 Phase 3 Paclitaxel
22 Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300) Active, not recruiting NCT02625623 Phase 3 Avelumab;Irinotecan;Paclitaxel
23 Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Active, not recruiting NCT02545504 Phase 3 Andecaliximab;Placebo;Leucovorin;5-fluorouracil;Oxaliplatin
24 A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer Active, not recruiting NCT02314117 Phase 3 Ramucirumab;Capecitabine;Cisplatin;Placebo;Fluorouracil
25 Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062) Active, not recruiting NCT02494583 Phase 3 cisplatin;5-FU;capecitabine
26 LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib Active, not recruiting NCT00680901 Phase 3 Lapatinib;Placebo;Capecitabine;Oxaliplatin
27 Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery Active, not recruiting NCT01107639 Phase 3 cisplatin;docetaxel
28 Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181) Active, not recruiting NCT02564263 Phase 3 paclitaxel;docetaxel;irinotecan
29 Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer Active, not recruiting NCT01196390 Phase 3 Carboplatin;Paclitaxel
30 A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer Terminated NCT02137343 Phase 3 Rilotumumab;Placebo;Cisplatin;Capecitabine
31 A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer Terminated NCT01450696 Phase 3 Capecitabine;Cisplatin;Herceptin
32 First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma Terminated NCT01697072 Phase 3 Rilotumumab;Epirubicin;Cisplatin;Capecitabine
33 A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer Terminated NCT01641939 Phase 2, Phase 3 Taxane;trastuzumab emtansine;trastuzumab emtansine
34 Efficacy and Safety of Panitumumab Combined With Docetaxel and Cisplatin as a First-line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Unknown status NCT01379807 Phase 2 panitumumab + docetaxel + cisplatino
35 Phase II Study of Neoadjuvant Taxotere, Cisplatin, and 5-Fluorouracil in Patients With Gastric or Gastroesophageal Junction Adenocarcinoma Unknown status NCT00763646 Phase 2 Taxotere, Cisplatin, and 5-FU
36 Apatinib in Combination With S-1 as First-Line Treatment in Patients With Advanced Gastric Cancer Unknown status NCT02525237 Phase 2 Apatinib;S-1
37 Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metastatic Gastric Cancer Unknown status NCT01359397 Phase 2 Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab;Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab, Trastuzumab
38 Study to Evaluate Safety and Efficacy of Perioperative Chemotherapy With Docetaxel, Cisplatin and Capecitabine (DCX) in Patients With Gastro-esophageal Cancer Unknown status NCT00865982 Phase 2 Docetaxel, Cisplatin, Capecitabine
39 Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH Unknown status NCT01855854 Phase 2 Icotinib
40 Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal Adenocarcinoma Unknown status NCT00964080 Phase 1, Phase 2 MBP-426/Leucovorin/5-FU
41 Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma Completed NCT00813072 Phase 2 PEP02;irinotecan;docetaxel
42 Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Completed NCT00084604 Phase 2 irinotecan hydrochloride;cisplatin
43 Study of Irinotecan and Docetaxel in Patients With Metastatic or Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma Completed NCT00183872 Phase 2 irinotecan, docetaxel
44 Explorative Phase II Study of Perioperative Treatment in Patients With Adenocarcinoma of the Gastroesophageal Junction or Stomach Completed NCT01472029 Phase 2 5-FU, leucovorin, docetaxel, oxaliplatin (FLOT), trastuzumab;Post-operative treatment trastuzumab mono therapy
45 Study of Oxaliplatin and Sorafenib Combination to Treat Gastric Cancer Relapsed After a Cisplatin Based Treatment Completed NCT01262482 Phase 2 Oxaliplatin;Sorafenib
46 Bortezomib in Treating Patients With Unresectable or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Completed NCT00074009 Phase 2 bortezomib
47 Pilot Study of Perioperative Docetaxel, Oxaliplatin, and 5-Fluorouracil (FLOT) in Gastroesophageal Adenocarcinoma Completed NCT01932580 Phase 2 FLOT (5-fluorouracil, oxaliplatin, docetaxel)
48 Docetaxel+Oxali+/-Cetux Met Gastric/GEJ Completed NCT00517829 Phase 2 Docetaxel;cetuximab;oxaliplatin
49 Oxaliplatin and 5-Fluorouracil With or Without Docetaxel in Elderly Patients (>65 y) With Stomach and Esophagus Cancer Completed NCT00737373 Phase 2 Docetaxel;5-Fluorouracil;Oxaliplatin;folinic acid
50 Cetuximab in Combination With S-1 and Cisplatin in Gastric Cancer Completed NCT01388790 Phase 2 Cetuximab;Cisplatin;S-1

Search NIH Clinical Center for Gastroesophageal Junction Adenocarcinoma

Genetic Tests for Gastroesophageal Junction Adenocarcinoma

Anatomical Context for Gastroesophageal Junction Adenocarcinoma

MalaCards organs/tissues related to Gastroesophageal Junction Adenocarcinoma:

41
Breast, Testes, Prostate, Endothelial, Lung, Bone, Lymph Node

Publications for Gastroesophageal Junction Adenocarcinoma

Articles related to Gastroesophageal Junction Adenocarcinoma:

(show top 50) (show all 78)
# Title Authors Year
1
Perioperative chemotherapy vs. neoadjuvant chemoradiation inA gastroesophageal junction adenocarcinoma : A population-based evaluation of the Munich Cancer Registry. ( 29071366 )
2018
2
Evaluation of Expression of Human Epidermal Growth Factor Receptor 2 (HER2) in Gastric and Gastroesophageal Junction Adenocarcinoma Using IHC and Dual-ISH. ( 29277796 )
2018
3
Ramucirumab for the treatment of metastatic gastric or gastroesophageal junction adenocarcinoma following disease progression on first-line platinum- or fluoropyrimidine-containing combination therapy in Japanese patients: a phase 2, open-label study. ( 29508095 )
2018
4
Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma. ( 29094609 )
2018
5
Testicular Metastasis from Recurrent Gastroesophageal Junction Adenocarcinoma: Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Findings. ( 29430123 )
2018
6
Unusual case of left atrial myxoma with gastroesophageal junction adenocarcinoma. ( 29338297 )
2018
7
Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study. ( 29691300 )
2018
8
Combined taxane-based chemotherapy and intensity-modulated radiotherapy with simultaneous integrated boost for gastroesophageal junction adenocarcinoma. ( 29664354 )
2018
9
Personalized therapy based on image for esophageal or gastroesophageal junction adenocarcinoma. ( 29666803 )
2018
10
Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough. ( 29703766 )
2018
11
Significance of blood neutrophil-to-lymphocyte ratio for prognostic stratification of patients with gastroesophageal junction adenocarcinoma in the era of the 8th edition of the American Joint Committee on Cancer (AJCC8) staging. ( 28500616 )
2017
12
Significance of baseline FDG-PET/CT scan as a method of staging regional lymph nodes in patients with operable distal oesophageal or gastroesophageal junction adenocarcinoma. ( 28524708 )
2017
13
Health-related quality of life after gastrectomy, esophagectomy, and combined esophagogastrectomy for gastroesophageal junction adenocarcinoma. ( 28852939 )
2017
14
HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. ( 28574779 )
2017
15
Efficacy and safety of first-line systemic chemotherapy with epirubicin, cisplatin plus 5-fluorouracil and docetaxel, cisplatin plus 5-fluorouracil regimens in locally advanced inoperable or metastatic gastric or gastroesophageal junction adenocarcinoma: A prospective phase II study from South India. ( 29199662 )
2017
16
Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma. ( 28424936 )
2017
17
External beam radiation and high-dose-rate brachytherapy for elderly patients with gastroesophageal junction adenocarcinoma. ( 28951752 )
2017
18
Clinical effectiveness and toxicity of second-line irinotecan in advanced gastric and gastroesophageal junction adenocarcinoma: a single-center observational study. ( 28491144 )
2017
19
HER2 status in Gastric and Gastroesophageal Junction Adenocarcinoma. ( 28588175 )
2017
20
Management and Reconstruction of a Gastroesophageal Junction Adenocarcinoma Patient Three Years after Pancreaticoduodenectomy: A Surgical Puzzle. ( 27635275 )
2016
21
Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. ( 26747859 )
2016
22
No Survival Difference with Neaodjuvant Chemoradiotherapy Compared with Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma: Results from the National Cancer Data Base. ( 27641320 )
2016
23
Positioning of second-line treatment for advanced gastric and gastroesophageal junction adenocarcinoma. ( 27774774 )
2016
24
Central nervous system relapse in patients with untreated her2-positive esophageal or gastroesophageal junction adenocarcinoma. ( 27198655 )
2016
25
Isolated Splenic Metastases of Her2+++ Gastroesophageal Junction Adenocarcinoma. ( 27065846 )
2016
26
Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial. ( 26354521 )
2015
27
Survey of Her2-neu Expression and its Correlation with Histology of Gastric Carcinoma and Gastroesophageal Junction Adenocarcinoma. ( 26625793 )
2015
28
Comparisons of Clinical Outcomes and Prognoses in Patients With Gastroesophageal Junction Adenocarcinoma, by Transthoracic and Transabdominal Hiatal Approaches: A Teaching Hospital Retrospective Cohort Study. ( 26683954 )
2015
29
Incidence of brain metastases in HER2+ gastric or gastroesophageal junction adenocarcinoma. ( 25753188 )
2015
30
Combined neutron brachytherapy with external beam radiation in patients with inoperable gastroesophageal junction adenocarcinoma. ( 25296599 )
2014
31
The safety and usefulness of neutron brachytherapy and external beam radiation in the treatment of patients with gastroesophageal junction adenocarcinoma with or without chemotherapy. ( 24774780 )
2014
32
Personalizing risk stratification by addition of PAK1 expression to TNM staging: Improving the accuracy of clinical decision for gastroesophageal junction adenocarcinoma. ( 25159681 )
2014
33
Distant lymph node metastases in gastroesophageal junction adenocarcinoma: impact of endoscopic ultrasound-guided fine-needle aspiration. ( 24949383 )
2013
34
Meningeal carcinomatosis: a metastasis from gastroesophageal junction adenocarcinoma. ( 24454393 )
2013
35
Prognostic importance and therapeutic implications of PAK1, a drugable protein kinase, in gastroesophageal junction adenocarcinoma. ( 24236193 )
2013
36
Results of docetaxel plus oxaliplatin (DOCOX) A+ cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: results of a randomised Phase 2 study. ( 23747051 )
2013
37
The metastasis-associated gene MTA3, a component of the Mi-2/NuRD transcriptional repression complex, predicts prognosis of gastroesophageal junction adenocarcinoma. ( 23671646 )
2013
38
The incidence and prognostic value of HER2 overexpression and cyclin D1 expression in patients with gastric or gastroesophageal junction adenocarcinoma in Israel. ( 23420289 )
2013
39
Gastroesophageal junction adenocarcinoma metastasizing to gingiva. ( 23776844 )
2013
40
A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma. ( 23921575 )
2013
41
HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population. ( 23656792 )
2013
42
Reconstructive options for gastroesophageal junction adenocarcinoma after Roux-en-Y gastric bypass. ( 23988286 )
2013
43
Snail1 correlates with patient outcomes in E-cadherin-preserved gastroesophageal junction adenocarcinoma. ( 24356933 )
2013
44
Unanswered questions in the management of gastroesophageal junction adenocarcinoma. ( 23714486 )
2013
45
Relationship between gastroesophageal junction adenocarcinoma and Helicobacter pylori infection in Japan. ( 22472851 )
2012
46
Postoperative intraperitoneal 5-fluoro-2'-deoxyuridine added to chemoradiation in patients curatively resected (R0) for locally advanced gastric and gastroesophageal junction adenocarcinoma. ( 21769462 )
2012
47
HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications. ( 22646280 )
2012
48
HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment. ( 21617522 )
2012
49
Results of postoperative radiochemotherapy of the patients with resectable gastroesophageal junction adenocarcinoma in Slovenia. ( 23412351 )
2012
50
Gastroesophageal junction adenocarcinoma of young patients who underwent curative surgery: a comparative analysis with older group. ( 21264755 )
2011

Variations for Gastroesophageal Junction Adenocarcinoma

Expression for Gastroesophageal Junction Adenocarcinoma

Search GEO for disease gene expression data for Gastroesophageal Junction Adenocarcinoma.

Pathways for Gastroesophageal Junction Adenocarcinoma

Pathways related to Gastroesophageal Junction Adenocarcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.05 ERBB2 IL1B
2 10.48 ERBB2 SNAI1

GO Terms for Gastroesophageal Junction Adenocarcinoma

Biological processes related to Gastroesophageal Junction Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of protein phosphorylation GO:0001934 9.16 ERBB2 IL1B
2 positive regulation of epithelial to mesenchymal transition GO:0010718 8.96 IL1B SNAI1
3 regulation of ERK1 and ERK2 cascade GO:0070372 8.62 ERBB2 IL1B

Sources for Gastroesophageal Junction Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....